58 related articles for article (PubMed ID: 34272321)
21. Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides?
Briganti V; Cuccurullo V; Di Stasio GD; Mansi L
Curr Radiopharm; 2019; 12(2):156-170. PubMed ID: 30827276
[TBL] [Abstract][Full Text] [Related]
22. Value of
Imperiale A; Boursier C; Sahakian N; Ouvrard E; Chevalier E; Sebag F; Addeo P; Taïeb D
J Nucl Med; 2022 Mar; 63(3):384-388. PubMed ID: 34272321
[TBL] [Abstract][Full Text] [Related]
23.
Ouvrard E; Mestier L; Boursier C; Lachachi B; Sahakian N; Chevalier E; Mikail N; Carullo J; Bando-Delaunay A; Walter T; Malouf GG; Addeo P; Poncet G; Sebag F; Lebtahi R; Goichot B; Taïeb D; Imperiale A
J Nucl Med; 2022 Dec; 63(12):1865-1870. PubMed ID: 35589408
[TBL] [Abstract][Full Text] [Related]
24. Carbidopa-assisted
Helali M; Addeo P; Heimburger C; Detour J; Goichot B; Bachellier P; Namer IJ; Taïeb D; Imperiale A
Ann Nucl Med; 2016 Nov; 30(9):659-668. PubMed ID: 27485404
[TBL] [Abstract][Full Text] [Related]
25. Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms.
Veenstra EB; de Groot DJA; Brouwers AH; Walenkamp AME; Noordzij W
Clin Nucl Med; 2021 Mar; 46(3):195-200. PubMed ID: 33323729
[TBL] [Abstract][Full Text] [Related]
26. Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment.
Mapelli P; Partelli S; Salgarello M; Doraku J; Pasetto S; Rancoita PMV; Muffatti F; Bettinardi V; Presotto L; Andreasi V; Gianolli L; Picchio M; Falconi M
Nucl Med Commun; 2020 Sep; 41(9):896-905. PubMed ID: 32796478
[TBL] [Abstract][Full Text] [Related]
27. Variants and Pitfalls of PET/CT in Neuroendocrine Tumors.
Imperiale A; Meuter L; Pacak K; Taïeb D
Semin Nucl Med; 2021 Sep; 51(5):519-528. PubMed ID: 33838874
[TBL] [Abstract][Full Text] [Related]
28. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.
Ambrosini V; Kunikowska J; Baudin E; Bodei L; Bouvier C; Capdevila J; Cremonesi M; de Herder WW; Dromain C; Falconi M; Fani M; Fanti S; Hicks RJ; Kabasakal L; Kaltsas G; Lewington V; Minozzi S; Cinquini M; Öberg K; Oyen WJG; O'Toole D; Pavel M; Ruszniewski P; Scarpa A; Strosberg J; Sundin A; Taïeb D; Virgolini I; Wild D; Herrmann K; Yao J
Eur J Cancer; 2021 Mar; 146():56-73. PubMed ID: 33588146
[TBL] [Abstract][Full Text] [Related]
29. Early
Leroy-Freschini B; Amodru V; Addeo P; Sebag F; Vix M; Brunaud L; Klein M; Bahougne T; Bachellier P; Castinetti F; Goichot B; Chevalier E; Taieb D; Imperiale A
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):686-695. PubMed ID: 30617961
[TBL] [Abstract][Full Text] [Related]
30. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.
Antwi K; Fani M; Heye T; Nicolas G; Rottenburger C; Kaul F; Merkle E; Zech CJ; Boll D; Vogt DR; Gloor B; Christ E; Wild D
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2318-2327. PubMed ID: 30054698
[TBL] [Abstract][Full Text] [Related]
31. Guideline for PET/CT imaging of neuroendocrine neoplasms with
Bozkurt MF; Virgolini I; Balogova S; Beheshti M; Rubello D; Decristoforo C; Ambrosini V; Kjaer A; Delgado-Bolton R; Kunikowska J; Oyen WJG; Chiti A; Giammarile F; Sundin A; Fanti S
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1588-1601. PubMed ID: 28547177
[TBL] [Abstract][Full Text] [Related]
32. Molecular imaging in the investigation of hypoglycaemic syndromes and their management.
Pattison DA; Hicks RJ
Endocr Relat Cancer; 2017 Jun; 24(6):R203-R221. PubMed ID: 28400403
[TBL] [Abstract][Full Text] [Related]
33. Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan.
Nockel P; Babic B; Millo C; Herscovitch P; Patel D; Nilubol N; Sadowski SM; Cochran C; Gorden P; Kebebew E
J Clin Endocrinol Metab; 2017 Jan; 102(1):195-199. PubMed ID: 27805844
[TBL] [Abstract][Full Text] [Related]
34. Effect of Carbidopa on 18F-FDOPA Uptake in Insulinoma: From Cell Culture to Small-Animal PET Imaging.
Detour J; Pierre A; Boisson F; Kreutter G; Lavaux T; Namer IJ; Kessler L; Brasse D; Marchand P; Imperiale A
J Nucl Med; 2017 Jan; 58(1):36-41. PubMed ID: 27609787
[TBL] [Abstract][Full Text] [Related]
35. Role of (68)Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study.
Prasad V; Sainz-Esteban A; Arsenic R; Plöckinger U; Denecke T; Pape UF; Pascher A; Kühnen P; Pavel M; Blankenstein O
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1593-600. PubMed ID: 26923247
[TBL] [Abstract][Full Text] [Related]
36. 18F-FDOPA PET/CT imaging of insulinoma revisited.
Imperiale A; Sebag F; Vix M; Castinetti F; Kessler L; Moreau F; Bachellier P; Guillet B; Namer IJ; Mundler O; Taïeb D
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):409-18. PubMed ID: 25367749
[TBL] [Abstract][Full Text] [Related]
37. Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia.
Tessonnier L; Sebag F; Ghander C; De Micco C; Reynaud R; Palazzo FF; Conte-Devolx B; Henry JF; Mundler O; Taïeb D
J Clin Endocrinol Metab; 2010 Jan; 95(1):303-7. PubMed ID: 19915018
[TBL] [Abstract][Full Text] [Related]
38. Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [(18)F]-dihydroxy-phenyl-alanine positron emission tomography.
Kauhanen S; Seppänen M; Nuutila P
J Clin Oncol; 2008 Nov; 26(32):5307-8; author reply 5308-9. PubMed ID: 18854556
[No Abstract] [Full Text] [Related]
39. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.
Reubi JC; Waser B
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):781-93. PubMed ID: 12707737
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
